Martin van Eickels - JoVE Visualize

Showing results (21-30 of 56) with videos related to

Pageof 6

Sort By:

The Journal of Clinical Investigation|May 3, 2003

Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-ARita Holtwick, Martin van Eickels, Boris V Skryabin, et al.

Circulation|January 14, 2004

17beta-estradiol antagonizes cardiomyocyte hypertrophy by autocrine/paracrine stimulation of a guanylyl cyclase A receptor-cyclic guanosine monophosphate-dependent protein kinase pathwayFawzi A Babiker, Leon J De Windt, Martin van Eickels, et al.

Journal of the American College of Cardiology|June 12, 2003

17-beta-estradiol increases cardiac remodeling and mortality in mice with myocardial infarctionMartin van Eickels, Richard D Patten, Mark J Aronovitz, et al.

The Lancet. Haematology|January 15, 2016

Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional studyWalter Ageno, Lorenzo G Mantovani, Sylvia Haas, et al.

Annals of Medicine|June 30, 2018

Left atrial thrombus resolution in non-valvular atrial fibrillation or flutter: biomarker substudy results from a prospective study with rivaroxaban (X-TRA)Kazuo Miyazawa, Daniele Pastori, Christoph Hammerstingl, et al.

Thrombosis and Haemostasis|October 25, 2013

A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustmentAlexander G G Turpie, Sylvia Haas, Reinhold Kreutz, et al.

Circulation|October 12, 2005

Enhanced activity of the myocardial Na+/H+ exchanger NHE-1 contributes to cardiac remodeling in atrial natriuretic peptide receptor-deficient miceAna Kilic, Ana Velic, León J De Windt, et al.

European Journal of Internal Medicine|October 22, 2018

Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosisLorenzo G Mantovani, Sylvia Haas, Reinhold Kreutz, et al.

American Heart Journal|March 31, 2015

An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI)C Michael Gibson, Roxana Mehran, Christoph Bode, et al.

International Journal of Cardiology|August 24, 2016

Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registrySeil Oh, Shinya Goto, Gabriele Accetta, et al.

Pageof 6

Showing results (21-30 of 56) with videos related to

Sort By:

Pageof 6

The Journal of Clinical Investigation|May 3, 2003

Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-ARita Holtwick, Martin van Eickels, Boris V Skryabin, et al.

Circulation|January 14, 2004

17beta-estradiol antagonizes cardiomyocyte hypertrophy by autocrine/paracrine stimulation of a guanylyl cyclase A receptor-cyclic guanosine monophosphate-dependent protein kinase pathwayFawzi A Babiker, Leon J De Windt, Martin van Eickels, et al.

Journal of the American College of Cardiology|June 12, 2003

17-beta-estradiol increases cardiac remodeling and mortality in mice with myocardial infarctionMartin van Eickels, Richard D Patten, Mark J Aronovitz, et al.

The Lancet. Haematology|January 15, 2016

Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional studyWalter Ageno, Lorenzo G Mantovani, Sylvia Haas, et al.

Annals of Medicine|June 30, 2018

Left atrial thrombus resolution in non-valvular atrial fibrillation or flutter: biomarker substudy results from a prospective study with rivaroxaban (X-TRA)Kazuo Miyazawa, Daniele Pastori, Christoph Hammerstingl, et al.

Thrombosis and Haemostasis|October 25, 2013

A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustmentAlexander G G Turpie, Sylvia Haas, Reinhold Kreutz, et al.

Circulation|October 12, 2005

Enhanced activity of the myocardial Na+/H+ exchanger NHE-1 contributes to cardiac remodeling in atrial natriuretic peptide receptor-deficient miceAna Kilic, Ana Velic, León J De Windt, et al.

European Journal of Internal Medicine|October 22, 2018

Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosisLorenzo G Mantovani, Sylvia Haas, Reinhold Kreutz, et al.

American Heart Journal|March 31, 2015

An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI)C Michael Gibson, Roxana Mehran, Christoph Bode, et al.

International Journal of Cardiology|August 24, 2016

Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registrySeil Oh, Shinya Goto, Gabriele Accetta, et al.

Pageof 6